Surfactant Therapy

Surfactant therapy delivers a lung-lubricating substance directly into a premature baby's airways to treat respiratory distress syndrome, a condition where the lungs lack enough natural surfactant to stay open between breaths. Without surfactant, the tiny air sacs in a premature infant's lungs tend to collapse, making breathing extremely difficult. This therapy has been one of the most significant advances in neonatal care, dramatically reducing deaths and complications from respiratory distress syndrome in premature infants. It is usually given soon after birth in babies showing signs of breathing difficulty.

Surfactant Therapy is recommended for patients diagnosed with specific conditions where other approaches have been insufficient. Your Neonatology specialist will assess your suitability based on your diagnosis, health history, and treatment goals.

The typical duration is A few minutes to administer, effects within hours. This may vary based on the complexity of your case and individual response to treatment.

Recovery typically takes Improvement in breathing is often seen within hours of administration, though the baby typically continues to need respiratory support and NICU monitoring for days to weeks depending on how premature they are. Chest X-rays and blood gas tests track ongoing lung recovery.. Your care team will provide specific instructions based on your response and overall health.

Side effects vary by individual and are detailed in the section above. Your specialist will discuss all risks and benefits with you before treatment begins. Serious adverse effects are uncommon but are part of the informed consent process.

Surfactant Therapy has a documented success rate of 85-90% at accredited facilities. Outcomes depend on disease stage, patient health, and adherence to the treatment plan and aftercare instructions.